Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Pharmaceutical Executive examined how leading drugmakers build and measure trust across their organizations and found that the foundation starts before reputation, ESG, or public communication. It starts with safe, effective, high-quality medicines and genuine regulatory compliance. The analysis matters for
Halo Pharma is preparing to launch a new sterile fill-finish platform in the United States, marking its first move into syringe, vial, and cartridge filling. The expansion responds to demand for domestic injectable capacity, while the Apotex partnership gives Halo
Bristol Myers Squibb plans to invest $2.3 billion in a new manufacturing campus at Generation Park in Houston, Texas. The company says the site will support next-generation medicines, create nearly 500 skilled jobs and expand U.S. production capacity. More importantly,
Pharma companies continue to increase AI investment, but expected gains in development timelines and success rates remain limited. In an August 10, 2026 analysis for Pharmaceutical Technology, Brian Drapeau argues that workforce qualification may be the missing link. The issue
The EDQM has introduced Ph. Eur. General Chapter 2.6.42 for procoagulant activity testing in human immunoglobulin preparations. EDQM announced the change in Strasbourg on 10 August 2026. The chapter will appear in Ph. Eur. Issue 13.3 in October and take
Thermo Fisher Scientific expects its customer base in India to grow by 15% to 20% over the next five years as biopharma research and manufacturing expand across the country. The company also forecasts continued double-digit growth, driven by rising demand
Scholar Rock will remove Novo Nordisk’s Bloomington, Indiana fill-finish facility from its apitegromab FDA application after the FDA classified an April 2026 inspection as Official Action Indicated (OAI). FDA review will now continue through a second U.S. fill-finish site. The
The European Medicines Agency (EMA) has updated its guidance on shortage prevention plans for medicines marketed in the EU, ahead of new legal requirements expected by mid-2027. The update matters because marketing authorisation holders (MAHs) must identify supply-chain vulnerabilities, classify
The FDA approved Moderna’s mFlusiva on August 6, 2026, making it the first mRNA-based influenza vaccine authorized in the United States. The agency granted traditional approval for adults aged 50 to 64 but used accelerated approval for those 65 and
The FDA granted accelerated approval to Replimune’s Tudriqev with nivolumab on August 6, 2026, for advanced melanoma after anti-PD-1 therapy. The decision is significant because FDA had previously rejected the application twice over efficacy concerns. For Regulatory Affairs and clinical